Skip to main content

Market Overview

AstraZeneca To Inject $360M In Irish API Manufacturing Site

AstraZeneca To Inject $360M In Irish API Manufacturing Site
  • AstraZeneca plc (NASDAQ: AZNwill invest $360 million to develop a manufacturing facility in Ireland to produce active pharmaceutical ingredients (APIs).
  • The planned investment at the Alexion Campus in College Park, Dublin, is expected to create about 100 highly skilled direct jobs.
  • "The future manufacturing of APIs for our medicines includes compounds with highly complex synthesis ... This significant investment will ensure the AstraZeneca supply network is fit for the future," said Pam Cheng, head of AstraZeneca's operations and IT.
  • The planned investment in Dublin is expected to support late-stage development and early commercial supply.
  • AstraZeneca said that the site could be developed further to add treatments such as antibody-drug conjugates and oligonucleotides.
  • Read Next: AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials.
  • Price Action: AZN stock is up 0.68% at $58.90 during the premarket session on the last check Tuesday.

Related Articles (AZN + AZNCF)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at